@article{fa78570994d540f6b34e6ff793797183,
title = "African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy",
abstract = "Susceptibility to peripheral neuropathy during antiretroviral therapy with nucleoside reverse-transcriptase inhibitors was previously associated with a European mitochondrial DNA (mtDNA) haplogroup among non-Hispanic white persons. To determine whether nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy was related to mtDNA variation in non-Hispanic black persons, we sequenced mtDNA of participants from AIDS Clinical Trials Group study 384. Of 156 non-Hispanic black persons with genomic data, 51 (33\%) developed peripheral neuropathy. In a multivariate model, African mtDNA subhaplogroup L1c was an independent predictor of peripheral neuropathy (odds ratio, 3.7 [95\% confidence interval, 1.1-12.0]). An African mtDNA subhaplogroup is for the first time implicated in susceptibility to nucleoside reverse-transcriptase inhibitor-associated toxicity.",
author = "Canter, \{Jeffrey A.\} and Robbins, \{Gregory K.\} and Doug Selph and Clifford, \{David B.\} and Kallianpur, \{Asha R.\} and Robert Shafer and Shawn Levy and Murdock, \{Deborah G.\} and Ritchie, \{Marylyn D.\} and Haas, \{David W.\} and Todd Hulgan",
note = "Funding Information: Financial support: Funding for the genomic sequencing and analyses was provided by the National Institutes of Health (NIH)/National Institute of Neurological Diseases and Stroke grant NS059330. The project was also supported by Award Number U01AI068636 from the National Institute of Allergy and Infectious Diseases. AIDS Clinical Trials Group (ACTG) Study 384 was also supported by grant AI38858 and by Agouron/Pfizer, Bristol Myers Squibb, and GlaxoSmithKline. The ACTG sites contributing DNA for these analyses were funded by NIH grants AI069513, AI34835, AI069432, AI069423, AI069477, AI069501, AI069474, AI069428, AI69467, AI069415, Al32782, AI27661, AI25859, AI069495, AI069471, AI069532, AI069452, AI069450, AI069556, AI069484, AI069472, AI34853, AI069465, AI069511, AI38844, AI069424, AI069434, AI46370, AI069502, and AI069419. The ACTG Human DNA Repository is supported by NIH grant RR024975. Additional NIH support included grants AI077505, AI54999, MH071205, HL087726, AI69495, and AI062435. Funding Information: Potential conflicts of interest: G.K.R. has received research support from Gilead Sciences, Schering-Plough and has served as a consultant for Abbott Laboratories, Boehringer-Ingelheim, and Tibotec. D.B.C. has received research grants from Pfizer, Schering Plough, Bavarian Nordic, NeurogesX, GlaxoSmithKline, Tibotec, Boehringer-Ingelheim, Gilead, and Biogen and has served on Scientific Advisory Boards or as a consultant for Biogen, Elan, Roche, Forest Labs, Genentech, GlaxoSmithKline, Millennium Consulting, Schering Plough, Bristol-Meyers Squibb, and Genzyme. D.W.H. has received research grants from Bavarian Nordic, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Merck, Tanox, and Tibotec and has served on Scientific Advisory Boards for Glaxo Smith Kline and Tibotec. T.H. has received research funding from Merck. All other authors: none reported.",
year = "2010",
month = jun,
day = "1",
doi = "10.1086/652419",
language = "English (US)",
volume = "201",
pages = "1703--1707",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "11",
}
SDG 3 Good Health and Well-being